New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 6, 2013
05:55 EDTABBV, ABBV, ABBV, MRK, MRK, MRK, PFE, PFE, PFE, RHHBY, RHHBY, RHHBY, SYK, SYK, SYK, TEVA, TEVA, TEVA, COV, COV, COV, CERN, CERN, CERN, BAYRY, BAYRY, BAYRY, ABT, ABT, ABT, LPNT, LPNT, LPNTAmerican Congress of Obstetrics and Gynecology to hold annual meeting
61st Annual Meeting to be held in New Orleans on May 4-8.
News For ABBV;ABT;BAYRY;CERN;COV;TEVA;SYK;RHHBY;PFE;MRK;LPNT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
November 12, 2014
07:22 EDTRHHBYAssociation of Molecular Pathology is holding annual meeting
2014 Annual Meeting of AMP is being held in National Harbor, Maryland on November 12-15.
06:22 EDTBAYRYZoetis price target raised to $49 from $44 at Citigroup
Citigroup raised its price target for Zoetis (ZTS) shares to $49 after activist Pershing Square confirmed the accumulation of a 10% stake in the company. Citi thinks Pershing is interested in advocating for a sale of Zoetis, potentially to Valeant (VRX) if its bid for Allergan (AGN) fails. Citi believes others, including Bayer (BAYRY), could be interested in acquiring Zoetis. It keeps a Buy rating on the stock.
05:32 EDTLPNTHospital sector downgraded to Market Weight at Wells Fargo
Wells Fargo downgraded the Hospital group to Market Weight from Overweight saying the Supreme Court's decision to hear the King v. Burwell case as well as the government's reduced expectations for exchange enrollment in 2015 are likely to remain an overhang on the sector through at least the end of June. Along with the group cut, Wells downgraded shares of HCA Holdings (HCA) and Community Health (CYH) to Market Perform from Outperform. The firm keeps Market Perform ratings on Acadia (ACHC), LifePoint Hospitals (LPNT), Tenet (THC) and Universal Health (UHS).
November 11, 2014
16:01 EDTMRKOptions Update; November 11, 2014
Subscribe for More Information
15:43 EDTRHHBY, MRK, PFELeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
09:37 EDTMRKActive equity options trading
Subscribe for More Information
09:06 EDTABBVAbbVie announces positive results from chronic hepatitis C patients study
Subscribe for More Information
09:04 EDTABBVEnanta announces results from TURQUOISE-I, CORAL-I studies
Subscribe for More Information
08:15 EDTLPNTUniversal Health recent pullback a buying opportunity, says Leerink
Subscribe for More Information
08:13 EDTABBVAbbVie announces positive results from Phase 2b study PEARL-I
Subscribe for More Information
08:11 EDTABBVEnanta announces rseults from Phase 2b PEARL-I study
Subscribe for More Information
08:10 EDTMRKMerck reports results from Phase 2 study of Grazoprevir/Elbasvir
Subscribe for More Information
07:24 EDTCOVMedtronic submits commitments to EU related to Covidien merger
Subscribe for More Information
November 10, 2014
16:07 EDTRHHBY, BAYRYUBS to hold a conference
UBS European Conference is being held in London, England on November 11-12.
15:54 EDTCOVAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:20 EDTMRKOn The Fly: Pre-market Movers
Subscribe for More Information
08:48 EDTMRKGilead rises after Merck presents data on HCV combo
Subscribe for More Information
08:36 EDTCOVBSD Medical names Clint Carnell as president and CEO
Subscribe for More Information
07:20 EDTMRKGilead overhang from Merck HCV combo removed, says Wells Fargo
Subscribe for More Information
November 9, 2014
18:58 EDTMRKMerck presents interim data from C-SWIFT study
Merck announced the presentation of interim data from the C-SWIFT study exploring the potential of a candidate triple-therapy regimen consisting of the fixed-dose combination of grazoprevir/elbasvir , the company’s investigational NS3/4A protease inhibitor and NS5A inhibitor, in combination with sofosbuvir, a nucleotide inhibitor for the treatment of chronic hepatitis C virus, HCV, infection. Preliminary findings in treatment-naïve HCV genotype 1- infected non-cirrhotic patients, following six and four weeks of treatment, and patients with cirrhotic disease, following eight and six weeks of treatment, will be presented by Dr. Eric Lawitz, vice president, scientific and research development, The Texas Liver Institute, San Antonio, TX and C-SWIFT lead investigator. This poster presentation is part of a late-breaking abstract session at the 65th American Association for the Study of Liver Diseases, AASLD, Annual Meeting, also known as The Liver Meeting. “These interim data provide a compelling proof-of-concept for the potential of an eight- or six-week triple therapy course in treatment-naive patients with genotype 1 disease, including cirrhotic patients,” said Dr. Lawitz. “These findings will inform the design of larger studies aimed at understanding the potential of short-duration triple therapy across multiple patient types.”
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use